Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia

Psychological Medicine

Volumn 27, Issue 5, 1997, Pages 1223-1225

  Yamada, K ^a   Kanba, S ^a   Anamizu, S ^a   Ohnishi, K ^a   Ashikari, I ^a   Yagi, G ^a   Asai, M ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; ERYTHROCYTE ENZYME; NEUROLEPTIC AGENT; OXYGEN RADICAL; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; ENZYME ACTIVITY; HUMAN; MALE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DYSKINESIA, DRUG-INDUCED; ERYTHROCYTES; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE;

EID: 0030881062     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0033291797005114     Document Type: Article

References (15)

1. Abdalla, D. S. P., Monteiro, H. P., Oliveira, J. A. C. & Bechara, J. H. (1986). Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clinical Chemistry 32, 805-807.
2. Dabiri, L. M., Pasta, D., Darby, J. K. & Mosbacher, D. (1994). Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. American Journal of Psychiatry 151, 925-926.
3. Egan, M. F., Hyde, T. M., Albers, G. W., Elkashef, A., Alexander, R. C., Reeve, A., Blum, A., Saenz, R. E. & Wyatt, R. J. (1992). Treatment of tardive dyskinesia with vitamin E. American Journal of Psychiatry 149, 773-777.
4. Elkashef, A. M., Ruskin, P. E., Bacher, N. & Barrett, D. (1990). Vitamin E in the treatment of tardive dyskinesia. American Journal of Psychiatry 147, 505-506.
5. Graham, D. G., Tiffany, S. M., Bell, W. R. & Gutknecht, W. F. (1978). Auto-oxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Molecular Pharmacology 14, 644-653.
6. Halliwell, B. (1989). Oxidants and the central nervous system: some fundamental questions. Acta Neurologica Scandinavica 126, 23-33.
7. Jeste, D. V., Lohr, J. B., Clark, K. & Wyatt, R. J. (1988). Pharmacological treatments of tardive dyskinesia in the 1980s. Journal of Clinical Psychopharmacology 8, s38-s48.
8. Lohr, J. B. (1991). Oxygen radicals and neuropsychiatric illness: some speculations. Archives of General Psychiatry 48, 1097-1106.
9. Lohr, J. B., Cadet, J. L., Lohr, M. A., Jeste, D. V. & Wyatt, R. J. (1987). Alpha-tocopherol in tardive dyskinesia. Lancet i, 913-914.
10. Lohr, J. B., Kuczenski, R., Bracha, H. S., Moir, M. & Jeste, D. V. (1990). Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biological Psychiatry 28, 535-539.
11. Matsumoto, T., Uchimura, H., Hirano, M., Kim, J,. Yokoo, H., Shimomura, M., Nakahara, T., Inoue, K. & Oomagari, K. (1983). Differential effects of acute and chronic haloperidol on homovanillic acid levels in discrete dopaminergic areas of rat brain. European Journal of Pharmacology 89, 27-33.
12. Moore, D. C., Glazer, W. M., Bowers, M. B., & Heninger, G. R. (1983). Tardive dyskinesia and plasma homovanillic acid. Biological Psychiatry 189, 1393-1402.
13. Oyanagui, Y. (1984). Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Analytical Biochemistry 142, 290-296.
14. Pall, H. S., Williams, A. C., Blake, D. R. & Lunec, J. (1987). Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet ii, 596-599.
15. Stein, L. & Wise, C. D. (1971). Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science 171, 1032-1036.